Another Trial Supports Low-Dose Abiraterone Acetate in mCRPC

/in , , /by

This study, published in JCO Global Oncology and focused on abiraterone acetate (AA), a drug used to treat metastatic castration-resistant prostate cancer, suggests that a smaller dose of AA is as effective as the standard dose (we already talked about another study pointing in the same direction in Singapore, but this sample is bigger). The […]

Read more